<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061798</url>
  </required_header>
  <id_info>
    <org_study_id>NL-66759</org_study_id>
    <nct_id>NCT04061798</nct_id>
  </id_info>
  <brief_title>ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.</brief_title>
  <acronym>ACTION-1</acronym>
  <official_title>ACTION-1: ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair, a Randomised Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dijklander Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dijklander Ziekenhuis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the ACTION-1 study is to determine whether ACT guided heparinization decreases
      thrombo-embolic complications (TEC) and mortality after elective open AAA surgery, without
      causing more bleeding complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heparin is used during open abdominal aortic aneurysm (AAA) surgery to reduce thrombo-embolic
      complications (TEC): such as myocardial infarction, stroke, peripheral embolic events and the
      related mortality. On the other hand, heparin may increase blood loss, causing harm for the
      patient.

      Heparin has an unpredictable effect in the individual patient. The effect of heparin can be
      measured by using the Activated Clotting Time (ACT). ACT measurement in open AAA repair could
      be introduced to ensure the individual patient of safe, tailor-made anticoagulation with a
      goal ACT of 200-220 seconds. A randomized controlled trial (RCT) has to prove that ACT guided
      heparinization would result in fewer TEC and lower mortality than a standardized bolus of
      heparin of 5 000 international units (IU), the current gold standard. ACT guided
      heparinization results in higher doses of heparin during operation and this should not result
      in significantly more bleeding complications of importance.

      The ACTION-1 study will evaluate the effect of weight dosed heparinization during open
      abdominal aortic aneurysm surgery.The study will be an international multi-centre single
      blind randomized controlled trial. Patients will be randomized using a computerized program
      (CASTOR EDC) with a random block size of a maximum of 8. The randomization will be stratified
      by participating centre. Separate evaluation of results and if complications can be labelled
      as TEC, will be performed by an Independent Central Adjudication Committee. The 3 members of
      this Committee will be blinded with regard to if the patient was randomized for ACT guided
      heparinization or standard bolus of 5 000 IU without ACT measurements.

      In the intervention group, heparin is given to reach an ACT of 200-220 seconds. Based on the
      ACT, an additional dose of heparin will be administered. Five minutes after every
      administration of heparin the ACT is measured. If the ACT is 200 seconds or longer, the next
      ACT measurement is performed every 30 minutes, until the end of the procedure or until new
      heparin administration is required (because of ACT &lt; 200 seconds). Depending on the ACT value
      near the end of surgery, protamine will be given to neutralize the effect of heparin.

      In the comparative group, a single dose of 5 000 IU of heparin will be given 3-5 minutes
      before clamping of the aorta. No ACT measurements will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention group:
Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
Comparative group:
A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patients will be randomized using a computerized program (CASTOR EDC) with a random block size of a maximum of 8. The randomization will be stratified by participating centre. The participant is blinded to the allocated treatment.
Separate evaluation of results and if complications can be labelled as TEC, will be performed by an Independent Central Adjudication Committee. The 3 members of this Committee will be blinded to the allocated treatment.
Since the care provider and investigator have to do the ACT measuring, it is impossible to blind them to the allocated treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of all thrombo-embolic complications (TEC) and all-cause mortality.</measure>
    <time_frame>Within 30 days or during the same admission in hospital</time_frame>
    <description>TEC are any complication as caused by thrombus or embolus perioperatively, including but not exclusively: myocardial infarction, leg ischemia, deep venous thrombosis, colon ischemia, transient ischemic attack (TIA)/stroke, graft thrombosis, peroperative thrombus requiring embolectomy or redo of an anastomosis, thrombus or embolus in organs or lower limbs and other peripheral thrombosis. Incidence of bleeding complications according to European multicenter study on Coronary Artery Bypass Grafting (E-CABG) classification, grade 1 and higher: per- or postoperative transfusion of 2 or more units of red blood cells, transfusion of platelets, transfusion of fresh frozen plasma or reoperation for bleeding during hospital stay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications (non-TEC).</measure>
    <time_frame>Within 30 days or during the same admission in hospital</time_frame>
    <description>All complications requiring re-operation, longer hospital stay, all other complications. Incidence of kidney injury as defined by RIFLE criteria: rise of serum creatinine &gt; 100% or decrease of estimated Glomerular Filtration Rate (eGFR) with 50%.32 Allergic reactions. ACT values (in intervention group), total heparin administration, protamine administration. Peroperative blood loss, blood transfusions either autologous or homologous, other blood products administration, total operative time, aortic clamping time, use of adjunctive haemostatic products, length of hospital (including ICU) stay. Health status as measured with the EQ-5D-5L. Economic and healthcare costs evaluation by the institute for Medical Technology Assessment (iMTA) Medical Consumption Questionnaire(IMCQ) and iMTA Productivity Cost Questionnaire (IPCQ) and addition of out-of-pocket expenses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <condition>Surgery</condition>
  <condition>Arterial Disease</condition>
  <arm_group>
    <arm_group_label>ACT guided heparinization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 000 IU of heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT guided heparinization</intervention_name>
    <description>If the ACT is &lt;180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.
If the ACT is &gt;200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is &gt;200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.
If the ACT at closure is 200-250 sec., 25 mg protamine should be administered. If &gt;250 sec., 50 mg protamine. If 180-200 sec., 10 mg protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again.</description>
    <arm_group_label>ACT guided heparinization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 000 IU of heparin</intervention_name>
    <description>A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.</description>
    <arm_group_label>5 000 IU of heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to speak and read in local language of trial hospital.

          -  Patients older than 18 years scheduled for elective, open repair of an iliac or
             abdominal aortic aneurysm distal of the Superior Mesenteric Artery (SMA) (DSAA segment
             C).

          -  Implantation of a tube or bifurcation prosthesis.

          -  Trans-abdominal or retroperitoneal surgical approach of aneurysm.

          -  Able and willing to provide written informed consent.

        Exclusion Criteria:

          -  Not able to provide written informed consent.

          -  Previous open or endovascular intervention on the abdominal aorta (previous surgery on
             other parts of the aorta or iliac arteries is not an exclusion criterion).

          -  History of coagulation disorders, heparin induced thrombocytopenia (HIT), allergy for
             heparin or thrombocyte pathology.

          -  Impaired renal function with EGFR below 30 ml/min.

          -  Acute open AAA surgery.

          -  Hybrid interventions.

          -  Connective tissue disorders.

          -  Dual anti-platelet therapy, which cannot be discontinued.

          -  Life expectancy less than 2 years.

          -  Inflammatory, mycotic or infected aneurysms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arno M Wiersema, MD, PhD</last_name>
    <phone>0031653444515</phone>
    <email>arno@wiersema.nu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent Jongkind, MD, PhD</last_name>
    <phone>0031229257257</phone>
    <email>v.jongkind@westfriesgasthuis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M PJ Rijnen, MD, PhD</last_name>
      <phone>003188 0053 077</phone>
      <email>mmpj.reijnen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUMC Location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. D. Blankensteijn, MD, PhD</last_name>
      <phone>003120 4444 444</phone>
      <email>j.blankensteijn@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUMC Location AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M JW Koelemay, MD, PhD</last_name>
      <phone>003120 566 9111</phone>
      <email>m.j.koelemaij@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elisabeth TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <state>Noord-Braband</state>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Heyligers, MD, PhD</last_name>
      <phone>003113 2210 000</phone>
      <email>j.heyligers@etz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L. Van Der Laan, MD, PhD</last_name>
      <phone>003176 5955 000</phone>
      <email>lvanderlaan@amphia.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J AW Teijink, MD, PhD</last_name>
      <phone>003140 2396 349</phone>
      <email>joep.teijink@catharinaziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijklander Ziekenhuis</name>
      <address>
        <city>Hoorn</city>
        <state>Noord-Holland</state>
        <zip>1624NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arno M Wiersema, MD, PhD</last_name>
      <phone>0031229208206</phone>
      <email>a.wiersema@westfriesgasthuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Vincent Jongkind, MD, PhD</last_name>
      <phone>0031229257257</phone>
      <email>v.jongkind@westfriesgasthuis.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7512 KZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Willigendael, MD, PhD</last_name>
      <phone>003153 4872 000</phone>
      <email>E.Willigendael@mst.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Pierie, MD, PhD</last_name>
      <phone>0003138 424 5000</phone>
      <email>m.pierie@isala.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groene Hart</name>
      <address>
        <city>Gouda</city>
        <state>Zuid-Holland</state>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. M. Schlejen, MD, PhD</last_name>
      <phone>0031182 505 050</phone>
      <email>Peter.Schlejen@ghz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. Van Schaik, MD, PhD</last_name>
      <phone>003171 5269 111</phone>
      <email>J.van_Schaik@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne</name>
      <address>
        <city>Leiderdorp</city>
        <state>Zuid-Holland</state>
        <zip>2353 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R. Hoencamp, MD, PhD</last_name>
      <phone>003171 5828 282</phone>
      <email>rhoencamp@alrijne.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Fioole, MD, PhD</last_name>
      <phone>003110 2911 911</phone>
      <email>FiooleB@maasstadziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rogier Kropman, MD. PhD</last_name>
      <phone>0031883203000</phone>
      <email>r.kropman@antoniusziekenhuis.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://nvvv-vaatchirurgie.nl/sites/nvvv-vaatchirurgie.nl/files/Document%20aorta%20aneurysmata%2C%206.2.pdf</url>
    <description>Document aorta aneurysmata; expert rapport voor doelmatig gebruik. Ned Ver v VchenZN.</description>
  </link>
  <reference>
    <citation>Burgers LT, Vahl AC, Severens JL, Wiersema AM, Cuypers PW, Verhagen HJ, Redekop WK. Cost-effectiveness of Elective Endovascular Aneurysm Repair Versus Open Surgical Repair of Abdominal Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2016 Jul;52(1):29-40. doi: 10.1016/j.ejvs.2016.03.001. Epub 2016 Apr 23.</citation>
    <PMID>27118618</PMID>
  </reference>
  <reference>
    <citation>Behrendt CA, Sedrakyan A, Rieß HC, Heidemann F, Kölbel T, Petersen J, Debus ES. Short-term and long-term results of endovascular and open repair of abdominal aortic aneurysms in Germany. J Vasc Surg. 2017 Dec;66(6):1704-1711.e3. doi: 10.1016/j.jvs.2017.04.040. Epub 2017 Aug 7.</citation>
    <PMID>28780975</PMID>
  </reference>
  <reference>
    <citation>Behrendt CA, Rieß HC, Schwaneberg T, Larena-Avellaneda A, Kölbel T, Tsilimparis N, Spanos K, Debus ES, Sedrakyan A. Incidence, Predictors, and Outcomes of Colonic Ischaemia in Abdominal Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2018 Oct;56(4):507-513. doi: 10.1016/j.ejvs.2018.06.010. Epub 2018 Jul 20.</citation>
    <PMID>30037737</PMID>
  </reference>
  <reference>
    <citation>Deery SE, O'Donnell TFX, Bodewes TCF, Dalebout BA, Pothof AB, Shean KE, Darling JD, Schermerhorn ML. Early reintervention after open and endovascular abdominal aortic aneurysm repair is associated with high mortality. J Vasc Surg. 2018 Feb;67(2):433-440.e1. doi: 10.1016/j.jvs.2017.06.104. Epub 2017 Sep 21.</citation>
    <PMID>28943011</PMID>
  </reference>
  <reference>
    <citation>Trenner M, Haller B, Storck M, Reutersberg B, Kallmayer MA, Eckstein HH. Trends in Patient Safety of Intact Abdominal Aortic Aneurysm Repair: German Registry Data on 36,594 Procedures. Eur J Vasc Endovasc Surg. 2017 May;53(5):641-647. doi: 10.1016/j.ejvs.2016.12.024. Epub 2017 Jan 19.</citation>
    <PMID>28110907</PMID>
  </reference>
  <reference>
    <citation>Hynes CF, Endicott KM, Iranmanesh S, Amdur RL, Macsata R. Reoperation rates after open and endovascular abdominal aortic aneurysm repairs. J Vasc Surg. 2017 May;65(5):1323-1328. doi: 10.1016/j.jvs.2016.09.053. Epub 2017 Jan 7.</citation>
    <PMID>28073669</PMID>
  </reference>
  <reference>
    <citation>Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R, Buskens E, Grobbee DE, Blankensteijn JD; Dutch Randomized Endovascular Aneurysm Management (DREAM)Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2004 Oct 14;351(16):1607-18.</citation>
    <PMID>15483279</PMID>
  </reference>
  <reference>
    <citation>Lo RC, Bensley RP, Hamdan AD, Wyers M, Adams JE, Schermerhorn ML; Vascular Study Group of New England. Gender differences in abdominal aortic aneurysm presentation, repair, and mortality in the Vascular Study Group of New England. J Vasc Surg. 2013 May;57(5):1261-8, 1268.e1-5. doi: 10.1016/j.jvs.2012.11.039. Epub 2013 Feb 4.</citation>
    <PMID>23384493</PMID>
  </reference>
  <reference>
    <citation>Wiersema A, Bruijninckx C, Reijnen M, Vos J, Van Delden O, Vahl A, Zeebregts C, Moll F. Perioperative prophylactic antithrombotic strategies in vascular surgery: current practice in the Netherlands. J Cardiovasc Surg (Torino). 2015 Feb;56(1):119-25. Epub 2013 Jan 22.</citation>
    <PMID>23337406</PMID>
  </reference>
  <reference>
    <citation>Wiersema AM, Jongkind V, Bruijninckx CM, Reijnen MM, Vos JA, van Delden OM, Zeebregts CJ, Moll FL; CAPPAStudy Group Consensus on Arterial PeriProcedural Anticoagulation. Prophylactic perioperative anti-thrombotics in open and endovascular abdominal aortic aneurysm (AAA) surgery: a systematic review. Eur J Vasc Endovasc Surg. 2012 Oct;44(4):359-67. doi: 10.1016/j.ejvs.2012.06.008. Epub 2012 Jul 24. Review.</citation>
    <PMID>22831869</PMID>
  </reference>
  <reference>
    <citation>Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S.</citation>
    <PMID>15383472</PMID>
  </reference>
  <reference>
    <citation>Finley A, Greenberg C. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg. 2013 Jun;116(6):1210-22. doi: 10.1213/ANE.0b013e31827e4e62. Epub 2013 Feb 13. Review.</citation>
    <PMID>23408671</PMID>
  </reference>
  <reference>
    <citation>Arsenault KA, Paikin JS, Hirsh J, Dale B, Whitlock RP, Teoh K, Young E, Ginsberg JS, Weitz JI, Eikelboom JW. Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. J Thorac Cardiovasc Surg. 2012 Oct;144(4):944-950.e3. doi: 10.1016/j.jtcvs.2012.05.065. Epub 2012 Jun 27.</citation>
    <PMID>22743176</PMID>
  </reference>
  <reference>
    <citation>Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Can J Cardiol. 1993 Nov;9(9):797-801.</citation>
    <PMID>8281479</PMID>
  </reference>
  <reference>
    <citation>Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001 Feb 20;103(7):961-6.</citation>
    <PMID>11181470</PMID>
  </reference>
  <reference>
    <citation>Kasapis C, Gurm HS, Chetcuti SJ, Munir K, Luciano A, Smith D, Aronow HD, Kassab EH, Knox MF, Moscucci M, Share D, Grossman PM. Defining the optimal degree of heparin anticoagulation for peripheral vascular interventions: insight from a large, regional, multicenter registry. Circ Cardiovasc Interv. 2010 Dec;3(6):593-601. doi: 10.1161/CIRCINTERVENTIONS.110.957381. Epub 2010 Nov 9.</citation>
    <PMID>21062999</PMID>
  </reference>
  <reference>
    <citation>Veerhoek D, Groepenhoff F, van der Sluijs MGJM, de Wever JWB, Blankensteijn JD, Vonk ABA, Boer C, Vermeulen CFW. Individual Differences in Heparin Sensitivity and Their Effect on Heparin Anticoagulation During Arterial Vascular Surgery. Eur J Vasc Endovasc Surg. 2017 Oct;54(4):534-541. doi: 10.1016/j.ejvs.2017.07.006. Epub 2017 Aug 9.</citation>
    <PMID>28802634</PMID>
  </reference>
  <reference>
    <citation>Coyne TJ, Wallace MC, Benedict C. Peri-operative anticoagulant effects of heparinization for carotid endarterectomy. Aust N Z J Surg. 1994 Oct;64(10):679-83.</citation>
    <PMID>7945064</PMID>
  </reference>
  <reference>
    <citation>Poisik A, Heyer EJ, Solomon RA, Quest DO, Adams DC, Baldasserini CM, McMahon DJ, Huang J, Kim LJ, Choudhri TF, Connolly ES. Safety and efficacy of fixed-dose heparin in carotid endarterectomy. Neurosurgery. 1999 Sep;45(3):434-41; discussion 441-2.</citation>
    <PMID>10493364</PMID>
  </reference>
  <reference>
    <citation>de Sousa AA, Dellaretti MA, Faglioni W Jr, Carvalho GT. Monitoring of activated coagulation time in carotid endarterectomy. Surg Neurol. 2005;64 Suppl 1:S1:6-9.</citation>
    <PMID>15967231</PMID>
  </reference>
  <reference>
    <citation>Saw J, Bajzer C, Casserly IP, Exaire E, Haery C, Sachar R, Lee D, Abou-Chebl A, Yadav JS. Evaluating the optimal activated clotting time during carotid artery stenting. Am J Cardiol. 2006 Jun 1;97(11):1657-60. Epub 2006 Apr 19.</citation>
    <PMID>16728233</PMID>
  </reference>
  <reference>
    <citation>Goldhammer JE, Zimmerman D. Pro: Activated Clotting Time Should Be Monitored During Heparinization For Vascular Surgery. J Cardiothorac Vasc Anesth. 2018 Jun;32(3):1494-1496. doi: 10.1053/j.jvca.2017.04.047. Epub 2017 Apr 26.</citation>
    <PMID>28943189</PMID>
  </reference>
  <reference>
    <citation>Dieplinger B, Egger M, Luft C, Hinterreiter F, Pernerstorfer T, Haltmayer M, Mueller T. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure. J Vasc Surg. 2018 Aug;68(2):400-407. doi: 10.1016/j.jvs.2017.11.079. Epub 2018 Mar 20.</citation>
    <PMID>29571622</PMID>
  </reference>
  <reference>
    <citation>Lee JM, Park EY, Kim KM, Won JC, Jung TK, Lee SK. Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution. J Int Med Res. 2018 Feb;46(2):873-882. doi: 10.1177/0300060517731952. Epub 2017 Oct 4.</citation>
    <PMID>28974132</PMID>
  </reference>
  <reference>
    <citation>Chia S, Van Cott EM, Raffel OC, Jang IK. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemost. 2009 Mar;101(3):535-40.</citation>
    <PMID>19277416</PMID>
  </reference>
  <reference>
    <citation>Biancari F, Ruggieri VG, Perrotti A, Svenarud P, Dalén M, Onorati F, Faggian G, Santarpino G, Maselli D, Dominici C, Nardella S, Musumeci F, Gherli R, Mariscalco G, Masala N, Rubino AS, Mignosa C, De Feo M, Della Corte A, Bancone C, Chocron S, Gatti G, Gherli T, Kinnunen EM, Juvonen T. European Multicenter Study on Coronary Artery Bypass Grafting (E-CABG registry): Study Protocol for a Prospective Clinical Registry and Proposal of Classification of Postoperative Complications. J Cardiothorac Surg. 2015 Jun 30;10:90. doi: 10.1186/s13019-015-0292-z.</citation>
    <PMID>26123033</PMID>
  </reference>
  <reference>
    <citation>Brascia D, Reichart D, Onorati F, Perrotti A, Ruggieri VG, Bounader K, Verhoye JP, Santarpino G, Fischlein T, Maselli D, Dominici C, Mariscalco G, Gherli R, Rubino AS, De Feo M, Bancone C, Gatti G, Santini F, Dalén M, Saccocci M, Faggian G, Tauriainen T, Kinnunen EM, Nicolini F, Gherli T, Rosato S, Biancari F. Validation of Bleeding Classifications in Coronary Artery Bypass Grafting. Am J Cardiol. 2017 Mar 1;119(5):727-733. doi: 10.1016/j.amjcard.2016.11.027. Epub 2016 Dec 3.</citation>
    <PMID>28024656</PMID>
  </reference>
  <reference>
    <citation>Mazzalai F, Piatto G, Toniato A, Lorenzetti R, Baracchini C, Ballotta E. Using protamine can significantly reduce the incidence of bleeding complications after carotid endarterectomy without increasing the risk of ischemic cerebral events. World J Surg. 2014 May;38(5):1227-32. doi: 10.1007/s00268-013-2347-4.</citation>
    <PMID>24276985</PMID>
  </reference>
  <reference>
    <citation>Yamamoto S, Sakakura K, Taniguchi Y, Yamamoto K, Wada H, Momomura SI, Fujita H. Safety of Reversing Anticoagulation by Protamine Following Elective Transfemoral Percutaneous Coronary Intervention in the Drug-Eluting Stent Era. Int Heart J. 2018 May 30;59(3):482-488. doi: 10.1536/ihj.17-352. Epub 2018 May 9.</citation>
    <PMID>29743410</PMID>
  </reference>
  <reference>
    <citation>Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, Dick F, van Herwaarden J, Karkos C, Koelemay M, Kölbel T, Loftus I, Mani K, Melissano G, Powell J, Szeberin Z, Esvs Guidelines Committee, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Kolh P, Lindholt JS, de Vega M, Vermassen F, Document Reviewers, Björck M, Cheng S, Dalman R, Davidovic L, Donas K, Earnshaw J, Eckstein HH, Golledge J, Haulon S, Mastracci T, Naylor R, Ricco JB, Verhagen H. Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2019 Jan;57(1):8-93. doi: 10.1016/j.ejvs.2018.09.020. Epub 2018 Dec 5. Erratum in: Eur J Vasc Endovasc Surg. 2020 Mar;59(3):494.</citation>
    <PMID>30528142</PMID>
  </reference>
  <reference>
    <citation>Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004 Aug;8(4):R204-12. Epub 2004 May 24. Review.</citation>
    <PMID>15312219</PMID>
  </reference>
  <reference>
    <citation>M Versteegh M, M Vermeulen K, M A A Evers S, de Wit GA, Prenger R, A Stolk E. Dutch Tariff for the Five-Level Version of EQ-5D. Value Health. 2016 Jun;19(4):343-52. doi: 10.1016/j.jval.2016.01.003. Epub 2016 Mar 30.</citation>
    <PMID>27325326</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 18, 2019</study_first_submitted>
  <study_first_submitted_qc>August 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dijklander Ziekenhuis</investigator_affiliation>
    <investigator_full_name>Arno Wiersema</investigator_full_name>
    <investigator_title>MD, PhD, Vascular Surgeon</investigator_title>
  </responsible_party>
  <keyword>ACT guided heparinization in open aortic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>under pre-defined conditions and contract</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>after data lock, 07-2024</ipd_time_frame>
    <ipd_access_criteria>contract with pre-defined criteria according to government regulation concerning science research</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

